Eurofins Scientific: Viracor-IBT Partners with the National Kidney Registry to Accelerate Living Donor Transplantation
August 14 2015 - 1:30AM
Business Wire
Regulatory News:
Eurofins Scientific (EUFI.PA) (Paris:ERF), the global leader in
bio-analytical testing, and one of the world leaders in genomic
services, is pleased to announce a partnership between The National
Kidney Registry (NKR) and Viracor-IBT Laboratories, a wholly-owned
subsidiary of Eurofins, to streamline pre-transplant serology
testing for kidney donors. The NKR selected Viracor-IBT as the
national laboratory to perform infectious disease screening for its
75 member centers. Fast and accurate preoperative serology testing
reduces paired kidney exchange or “swap” failures and increases the
number of patients transplanted in NKR facilitated swaps. With so
many lives involved, time is of the essence and streamlined
logistics are critical; delayed test results can delay
transplants.
In describing the selection of Viracor-IBT for national
laboratory services, Garet Hil, Founder and CEO of the NKR said,
“Infectious disease screening is a critical part of the paired
exchange process. These tests need to be fast and accurate;
otherwise swaps can be delayed, or worse, cancelled. Through our
partnership with Viracor-IBT we further streamline the pre-op
serology testing process, reducing the turnaround for these tests
to under two days from as much as 10 days, while providing secure
electronic transmission of the results.”
Julie Kliegl, President of Viracor-IBT added, “Like the NKR,
Viracor-IBT is passionate about helping transplant patients. As a
laboratory committed to providing test results faster when it
matters most, Viracor-IBT is thrilled to partner with the NKR on
this critical program that accelerates donor-recipient matching and
increases living donor transplantation.”
The NKR and Viracor-IBT are continually working together to
identify additional areas in which this collaboration can benefit
transplant donors, recipients and hospital services.
For more information please visit
http://www.eurofins.com
Notes for the editor:
About National Kidney RegistryThe National Kidney
Registry (www.kidneyregistry.org) is a nonprofit organization with
the mission to save and improve the lives of people facing kidney
failure by increasing the quality, speed, and number of living
donor transplants.
Eurofins – a global leader in bio-analysisEurofins
Scientific is the world leader in food and pharmaceutical products
testing. It is also number one in the world in the field of
environmental laboratory services and one of the global market
leaders in agroscience, genomics, discovery pharmacology and
central laboratory services.
With about 19,000 staff in more than 200 laboratories across 38
countries, Eurofins offers a portfolio of over 130,000 reliable
analytical methods for evaluating the safety, identity,
composition, authenticity, origin and purity of biological
substances and products. The Group provides its customers with
high-quality services, accurate results on time and
Eurofins is committed to pursuing its dynamic growth strategy by
expanding both its technology portfolio and its geographic reach.
Through R&D and acquisitions, the Group draws on the latest
developments in the field of biotechnology and analytical chemistry
to offer its clients unique analytical solutions and the most
comprehensive range of testing methods.
As one of the most innovative and quality oriented international
players in its industry, Eurofins is ideally positioned to support
its clients’ increasingly stringent quality and safety standards
and the expanding demands of regulatory authorities around the
world.
The shares of Eurofins Scientific are listed on the Euronext
Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg
ERF FP).
Important disclaimer:
This press release contains forward-looking statements and
estimates that involve risks and uncertainties. The forward-looking
statements and estimates contained herein represent the judgement
of Eurofins Scientific’ management as of the date of this release.
These forward-looking statements are not guarantees for future
performance, and the forward-looking events discussed in this
release may not occur. Eurofins Scientific disclaims any intent or
obligation to update any of these forward-looking statements and
estimates. All statements and estimates are made based on the data
available to the Company as of the date of publication, but no
guarantee can be made as to their validity.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150813005899/en/
Viracor-IBTJenni Miller, Corporate CommunicationsPhone: +1 800
305 5198E-mail: jenni.miller@viracoribt.comorEurofins
ScientificInvestor RelationsPhone: +32 2 766 1620E-mail:
ir@eurofins.com
Enerplus (NYSE:ERF)
Historical Stock Chart
From Jun 2024 to Jul 2024
Enerplus (NYSE:ERF)
Historical Stock Chart
From Jul 2023 to Jul 2024